Headache最新文献

{"title":"Association between obstructive sleep apnea and migraine: A United States population-based cohort study.","authors":"Thomas Yen-Ting Chen, Tina Yi-Jin Hsieh, Yu-Hsun Wang, Renin Chang, Yao-Min Hung, James Cheng-Chung Wei","doi":"10.1111/head.14904","DOIUrl":"10.1111/head.14904","url":null,"abstract":"<p><strong>Objective: </strong>To determine the association between obstructive sleep apnea (OSA) and the incidence of migraine using a large population-based dataset, as well as to identify the at-risk target groups.</p><p><strong>Background: </strong>Epidemiological and biochemical studies have provided evidence for the close connection between sleep disorders and migraine. Understanding the connections between OSA and migraine, as well as their shared risk factors, may provide new perspectives on the pathophysiology of both OSA and migraine and novel approaches to managing and treating these conditions.</p><p><strong>Methods: </strong>This retrospective cohort study used data from the TriNetX network from 2010 to 2021. We compared 196,864 adult participants with OSA to a group of 196,864 participants who had never been diagnosed with OSA (1:1 propensity score-matching for age, sex, race, comorbidities, and body mass index [BMI] categories) in relation to the risk of incident migraine. We performed subgroup analyses based on age (18-39, 40-59, ≥60 years), sex (female, male), race (White, Black or African American, Asian), BMI categories (<18.5, 18.5-24.9, 25-29.9, ≥30 kg/m²), and the presence of hypoxemia (yes, no). Sensitivity analyses were performed to validate our findings.</p><p><strong>Results: </strong>During the follow-up period, 12,613 (6.4%) and 6356 participants (3.2%) developed migraine in the OSA and non-OSA cohorts, respectively. Patients with OSA were found to have a 1.85-fold risk (hazard ratio [HR] 1.85; 95% confidence interval [CI] 1.79-1.90) of incident migraine when compared to those without OSA, after accounting for age, sex, race, and baseline comorbidities. The results were consistent in sensitivity analyses (test-negative design: HR 1.39, 95% CI 1.28-1.49) and also cross-validated in a different dataset from TriNetX (Global Collaborative Research Network: HR 1.88, 95% CI 1.82-1.93). The results of subgroup analysis by sex, age, race, BMI categories, and the presence of hypoxemia were generally consistent.</p><p><strong>Conclusion: </strong>We found OSA to be associated with an elevated risk of developing migraine using a large United States nationwide database, and the association was generalizable across sex, age, race, and BMI categories. Our results suggest that awareness of migraine should be increased among patients with OSA. The findings also encourage further research to clarify the role of obesity and overweight in the relationship between OSA and migraine, as well as the potential benefits of body weight control for those with these two comorbid conditions.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"608-618"},"PeriodicalIF":5.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidden headache hero: Dr. Bernice Grafstein, cortical spreading depolarization, and the advancement of women in neuroscience.","authors":"Joseph E Safdieh, Teresa A Milner, Matthew S Robbins","doi":"10.1111/head.14930","DOIUrl":"10.1111/head.14930","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"666-667"},"PeriodicalIF":5.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Youth with high-frequency headaches due to migraine are more vulnerable to non-cephalic pain complaints.","authors":"Brooke L Reidy, Scott W Powers, Christopher D King, Marielle Kabbouche, Joanne Kacperski, Andrew D Hershey","doi":"10.1111/head.14931","DOIUrl":"10.1111/head.14931","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"655-657"},"PeriodicalIF":5.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility, acceptability, and fidelity of remote-delivered abbreviated mindfulness-based cognitive therapy interventions for patients with migraine and depressive symptoms.","authors":"Elizabeth K Seng, Jacob Hill, Annie Kate Reeder, Pallavi Visvanathan, Rebecca E Wells, Richard B Lipton, Mia Minen, Amanda J Shallcross","doi":"10.1111/head.14857","DOIUrl":"10.1111/head.14857","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This study was an open-label single-arm clinical trial evaluating the fidelity, feasibility, acceptability, and clinical signal of abbreviated mindfulness-based cognitive therapy (MBCT-brief) delivered either via telephone (MBCT-T) or by video conferencing (MBCT-V) for people with migraine and comorbid depressive symptoms.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Migraine is commonly comorbid with elevated depressive symptoms. MBCT reduces depressive symptoms and shows promise to reduce migraine-related disability. An abbreviated and remotely delivered version of MBCT could increase access to care.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;People with migraine and elevated depressive symptoms were recruited from a large urban health system. Participants were assigned in blocks of eight to receive an evidence-based MBCT-brief treatment, including eight weekly group classes and home practice delivered via telephone (MBCT-T) or video (MBCT-V); MBCT-T was randomly selected for the first block. Sessions were recorded and coded for treatment fidelity. Feasibility was assessed via session attendance (primary), homework completion, recruitment rate, and survey completion rate. Acceptability was assessed via the eight-item Client Satisfaction Questionnaire (CSQ-8; primary), the Credibility/Expectancy Questionnaire (CEQ), the System Usability Scale (SUS), and items assessing survey acceptability. Participants completed the Headache Disability Inventory (HDI) and Quick Inventory of Depressive Symptomatology-Self Report 16-item (QIDS-SR&lt;sub&gt;16&lt;/sub&gt;) at baseline, mid-treatment, and post-treatment. Feasibility and acceptability rates were compared to a priori benchmarks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Participants (n = 16) were all female with a mean (standard deviation [SD]) age of 45 (13) years, the majority of whom identified as White (13/16, 81%) and non-Hispanic (14/16, 88%). The intervention met the a priori criteria set for therapist fidelity to treatment protocol (mean [SD] MBCT-Treatment Acceptability and Competence Scale Adherence score 2.9 [0.2]), feasibility (mean [SD] session attendance was 7.9/8 [0.3]), and acceptability (mean [SD] CSQ-8 score 28.8 [3.3]) for the entire sample and for each treatment arm. The usability of the remote-delivery system was high across study participants (mean [SD] SUS score 84.8 [11.0]). Survey procedures were broadly deemed acceptable, with at least 80% participants either endorsing \"Agree\" or \"Strongly Agree\" across all items. Using Wilcoxon tests, we observed significant reductions in both the HDI (pre-treatment median [interquartile range] score 63 [40, 70] vs. post-treatment 36 [26, 54], p = 0.004) and the QIDS-SR&lt;sub&gt;16&lt;/sub&gt; (pre-treatment median [interquartile range] score 8 [5, 13] vs. post-treatment 4 [3, 6], p = 0.003).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;We found that remotely delivered MBCT-brief for migraine and depressive symptoms was feasible and acceptable to patients in both the telep","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"545-557"},"PeriodicalIF":5.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Headache in patients with systemic lupus erythematosus: A matched case-control study.","authors":"Igor de Oliveira, Bruno Rodrigo de Fontes, Henrique de Ataíde Mariz, Angela Luzia Branco Pinto Duarte, Pedro Augusto Sampaio Rocha-Filho","doi":"10.1111/head.14919","DOIUrl":"10.1111/head.14919","url":null,"abstract":"<p><strong>Objectives: </strong>To compare the prevalence and characteristics of headaches between patients with systemic lupus erythematosus (SLE) and people without the disease and to assess whether there was a relationship between headaches and disease activity.</p><p><strong>Background: </strong>Headache is a common symptom in patients with SLE; however, the effect of SLE on headaches is not fully known.</p><p><strong>Methods: </strong>This was a case-control study. Individuals with and without SLE matched by age and sex were compared. All participants were assessed by a neurologist. A semi-structured questionnaire, the six-item Headache Impact Test (HIT-6) and the Hospital Anxiety and Depression Scale were used. Disease activity was measured by a rheumatologist using the Physician Global Assessment (PGA) and quantified using the modified Systemic Lupus Erythematosus Disease Activity Index 2000 scale (modified SLEDAI-2K). Data were collected between November 2021 and January 2023.</p><p><strong>Results: </strong>A total of 228 individuals were included, 114 in each group. The SLE group presented with more moderate/severe headache attacks than the controls (odds ratio [OR] 2.45, 95% confidence interval [CI] 1.21-4.95; p = 0.013). When comparing patients with active SLE and those without disease activity, there was no difference in the prevalence (OR 1.48, 95% CI 0.38-5.74), type (migraine: OR 1.69, 95% CI 0.71-3.99; tension-type headache: OR 0.64, 95% CI 0.25-1.68), frequency (4; 2-15 vs. 3; 1-12 days/month; p = 0.250), intensity (moderate/severe intensity: OR 0.59, 95% CI 0.19-1.82), or impact of headache (HIT-6: 61; 50-65 vs. 56; 45-63; p = 0.278). The magnitude of SLE activity (modified SLEDAI-2K) demonstrated no statistically significant association with the impact (standardized beta coefficient: 0.02, 95% CI -0.05 to 0.09; p = 0.792) or monthly frequency of headache (standardized beta coefficient: 0.09, 95% CI -0.08 to 0.26; p = 0.275).</p><p><strong>Conclusions: </strong>Headache is a common symptom in SLE, although the prevalence was similar to that of the controls without the disease. While patients with SLE had more intense headache attacks than the controls without SLE, there was no association between headache and SLE activity.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"568-577"},"PeriodicalIF":5.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME (US) study.","authors":"Dawn C Buse, E Jolanda Muenzel, Anthony J Zagar, Ali Sheikhi Mehrabadi, Robert E Shapiro, Gilwan Kim, Sait Ashina, Robert A Nicholson, Richard B Lipton","doi":"10.1111/head.14925","DOIUrl":"10.1111/head.14925","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To estimate rates of migraine progression and assess predictors of progression in a large, longitudinal cohort study using the traditional definition and two alternative definitions of migraine progression.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Traditionally, migraine progression is defined as moving from episodic migraine (EM) with ≤ 14 monthly headache days (MHD) to chronic migraine (CM) with ≥ 15 MHDs of which 8 are attributable to migraine. This definition does not take into account changes in the full range of potential headache days, disability, or impact on function.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The Observational Survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME) study identified, characterized, and followed a representative sample of adults with migraine in the United States. Migraine was defined based on the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria. We estimated rates of migraine progression at 1 year of follow-up using three definitions: (1) traditional EM-to-CM transition, (2) increase of ≥ 5 MHDs (MHD progression), and (3) increase of ≥ 5 points on the Migraine Disability Assessment (MIDAS) scale (MIDAS progression). The analysis identified sociodemographic, clinical, and migraine-related characteristics associated with each definition of progression from a set of 67 candidates and then determined the association with progression for each candidate predictor and each definition of progression.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 11,634 participants met ICHD-3 criteria for migraine at baseline and completed the 1-year follow-up survey. The average age was 48.2 years, and average years living with migraine was 22.8 years. The sample was 75.6% female (8793/11,634), 84.4% White (9814/11,634), 6.5% Black (757/11,634), and 7.6% Hispanic (889/11,634). The majority (89.2%, 10,374/11,634) had EM at baseline, and among these, 4.7% progressed to CM over 1 year of follow-up. Rates of progression at 1 year were higher using other definitions of progression, with 9.6% (1087/11,329) reporting an increase in ≥ 5 MHDs and 21.7% (2519/11,630) reporting an increase of ≥ 5 MIDAS points. Across all three definitions of progression, ever taking preventive medications for migraine placed people at lower odds of progressing (odds ratio [95% confidence interval]: EM-to-CM transition, 0.7 [0.57-0.85]; MHD progression, 0.9 [0.75-1.00]; MIDAS progression, 0.8 [0.73-0.91]), while the presence of depression placed people at higher odds of progressing (odds ratio [95% confidence interval]: EM-to-CM transition, 1.3 [1.05-1.69]; MHD progression, 1.4 [1.21-1.67]; MIDAS progression, 1.2 [1.04-1.34]).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This work expands the concept of migraine progression, exploring two alternative definitions that modify the potential range of MHD changes and take disability into account. This analysis identified never having used preventive medications f","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"589-607"},"PeriodicalIF":5.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The \"central vein sign\" to differentiate multiple sclerosis from migraine.","authors":"Giulia Silvestri, Luca Roccatagliata, Francesco Tazza, Simona Schiavi, Alberto Coccia, Monica Bandettini Di Poggio, Maria Cellerino, Alessio Signori, Cinzia Finocchi, Antonio Uccelli, Matilde Inglese, Caterina Lapucci","doi":"10.1111/head.14902","DOIUrl":"10.1111/head.14902","url":null,"abstract":"<p><strong>Objective: </strong>To investigate, in two cohorts including patients with multiple sclerosis (MS) and migraine, (i) the prevalence of the \"central vein sign\" (CVS), (ii) the spatial distribution of positive CVS (CVS+) lesions, (iii) the threshold of CVS+ lesions able to distinguish MS from migraine with high sensitivity and specificity.</p><p><strong>Methods: </strong>A total of 70 patients with MS/clinically isolated syndrome and 50 age- and sex-matched patients with migraine underwent a 3-T magnetic resonance imaging scan. The CVS was evaluated according to current guidelines, excluding eight patients with migraine who did not show white matter (WM) lesions. A receiver operating characteristic curve analysis was performed to identify the best threshold in terms of proportion of CVS+ lesions and the absolute number of CVS+ lesions able to differentiate MS from migraine.</p><p><strong>Results: </strong>Lesion volume was different between CVS+ and CVS negative lesions (median 1043 vs. 176.5 mm³ for MS cohort; median 35.1 vs. 52.2 mm³ for migraine cohort; p < 0.001 for all). A higher proportion of CVS+ lesions was associated with a higher probability of being diagnosed as MS (adjusted odds ratio 1.09, 95% confidence interval [CI] 1.04-1.14; p < 0.001). CVS+ lesion volume and number were higher in MS with respect to migraine, both considering the whole brain and its subregions (p < 0.001). The proportion of CVS+ lesions in juxtacortical and infratentorial areas was higher in MS than in migraine (p = 0.015 and p = 0.034, respectively). The best CVS proportion-based threshold able to differentiate MS from migraine was 35.0% (sensitivity 97.1%, specificity 85.7%) with an area under the curve of 0.95 (95% CI 0.90-1.00). The \"select 6\" rule seemed to be preferable in terms of specificity with respect to the \"select 3\" rule.</p><p><strong>Conclusions: </strong>A CVS proportion-based threshold of 35.0% is capable of distinguishing MS from migraine with high sensitivity and specificity. The \"select 6\" algorithm may be useful in the clinical setting.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"558-567"},"PeriodicalIF":5.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Migraine and spontaneous coronary artery dissection: A retrospective case-control study.","authors":"Juleen C Lewis, Yulia Orlova, Gretchen E Tietjen, Chia-Chun Chiang, Andrea M Harriott","doi":"10.1111/head.14935","DOIUrl":"https://doi.org/10.1111/head.14935","url":null,"abstract":"<p><strong>Objective: </strong>The objective was to determine if migraine is independently associated with a greater odds of spontaneous coronary artery dissection (SCAD) in a case-control study.</p><p><strong>Background: </strong>There is growing evidence that migraine is associated with SCAD, a non-atherosclerotic, non-traumatic cause of myocardial infarction. However, few studies have examined the independent association between migraine and SCAD.</p><p><strong>Methods: </strong>A total of 1295 SCAD cases and 1291 (1:1) age, sex, and race/ethnicity matched controls presenting to the Boston, Massachusetts area, using the International Classification of Diseases ninth revision and 10th revision codes from our Research Patient Data Registry, were identified between the years 1990 and 2022. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated. For mediation, total effects, natural direct, and indirect effects were estimated using causal inference. Receiver operating characteristic (ROC) curves and area under the curve (AUC) was used to determine predictive power. Statistical significance was defined as p < 0.05.</p><p><strong>Results: </strong>Adjusting for age, sex, and race/ethnicity, the data demonstrated an almost two-fold increased odds of SCAD in patients with migraine (aOR 1.96, 95% CI 1.48-2.6; p < 0.001). There was no effect of aura phenotype on this association. Fibromuscular dysplasia (FMD) was found only in patients with SCAD (n = 133). After accounting for vascular risk factors, there was no longer an independent association between migraine and SCAD (aOR 0.90, 95% CI 0.63-1.29; p = 0.568). Using a model that adjusted for only demographic variables produced a ROC curve with the lowest predictive power (AUC 0.55) for SCAD, while the vascular risk factor-adjusted model had a higher predictive power (AUC 0.83). Hypertension appeared to mediate some of the effect of migraine on SCAD (proportion of effect mediated 0.70). FMD was highly associated with an increased risk of SCAD. There remained no independent association between SCAD and migraine when FMD was included in the model.</p><p><strong>Conclusions: </strong>The migraine-SCAD association can be partially attributed to the connection between migraine and vascular comorbidities including hypertension and FMD.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Afterimage duration differs for migraine with or without aura.","authors":"Florian Rimmele, Julia Teuber, Britta Müller, Simeon Giesen, Johannes Drescher, Jörg Scheidt, Uwe Walter, Peter Kropp, Tim P Jürgens","doi":"10.1111/head.14934","DOIUrl":"https://doi.org/10.1111/head.14934","url":null,"abstract":"<p><strong>Background: </strong>It is controversial to what extent afterimages, as distinct visual phenomena, are altered in patients with migraine and whether they have a specific role in migraine pathophysiology.</p><p><strong>Objective: </strong>The aim of this cross-sectional study was to investigate the duration of afterimages in patients with migraine, migraine with aura (MwA), and migraine without aura (MwoA), compared to healthy controls (HCs).</p><p><strong>Methods: </strong>Adults with migraine, MwA, and MwoA, diagnosed according to The International Classification of Headache Disorders, third edition criteria and HCs without relevant headache history were included. Initially, factors affecting the experimental setting of testing afterimage latency were determined. Then, afterimage duration was measured in the two study groups (MwA and MwoA) and the HC group. Patient characteristics, intraocular pressure, and relevant comorbid conditions, as well as scales on depressive symptoms (nine-item Patient Health Questionnaire) and headache-specific psychosocial impairment (six-item Headache Impact Test) were recorded. Lastly, the role of different stimulus colors, as well as habituation effects after repeated stimulation, were investigated.</p><p><strong>Results: </strong>The main study included 174 participants (40 with MwA, 53 with MwoA, and 81 HCs). The duration of the afterimage in patients with MwA was significantly longer than in HCs, at a mean (standard error of the mean [SEM]) of 12.6 (2.6) versus 5.5 ( 0.3) s (p = 0.035), while there was no significant difference between patients with MwoA (mean [SEM] 7.7 [1.6] s; p = 0.510) and HCs. There was also no significant effect of stimulus color on afterimage latency (mean [SEM] red: 8.9 [1.2] s and black: 8.4 [1.2] s).</p><p><strong>Conclusion: </strong>We found significantly longer afterimage duration in patients with MwA compared to both HCs and patients with MwoA. Furthermore, partially selective stimulation of retinal rods and cones by different stimulus colors had no effect on afterimage duration suggesting a relevant subcortical and/or cortical modulation in migraine aura with increased excitability.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient satisfaction with calcitonin gene-related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study.","authors":"Alba López-Bravo, Ane Mínguez-Olaondo, Candela Nieves-Castellanos, Marta Ruibal-Salgado, Noemí Morollón Sánchez-Mateos, María Pilar Navarro-Pérez, Alicia Alpuente, Marta Torres-Ferrús, Jésica García-Ull, Ana Gago-Veiga, David García-Azorín, Alicia González-Martínez, Álvaro Sierra, Sonia Santos-Lasaosa","doi":"10.1111/head.14913","DOIUrl":"https://doi.org/10.1111/head.14913","url":null,"abstract":"<p><strong>Background: </strong>Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are the first migraine-specific prophylactic medication. Clinical data regarding patient treatment satisfaction (TS) with CGRP mAbs are limited.</p><p><strong>Methods: </strong>A multicenter prospective cohort study was conducted in patients with ≥8 headache days/month who started treatment with erenumab, galcanezumab, or fremanezumab. Monthly migraine days (MMD), monthly headache days (MHD), Migraine Disability Assessment (MIDAS), and the six-item Headache Impact Test (HIT-6) scores were collected. Patients' satisfaction with treatment (effectiveness, convenience, side effects, and global satisfaction) was assessed by the Treatment Satisfaction Questionnaire for Medication, version 1.4 (TSQM-1.4©).</p><p><strong>Results: </strong>A total of 400 patients were included. The median (interquartile range [IQR]) TS scores were high (≥70%) across all domains of the TSQM-1.4 after 3 and 6 months of CGRP mAb therapy: 72.2 (50.0-83.3) and 83.3 (61.1-88.9) for effectiveness, 83.3 (72.2-100) and 83.3 (77.8-100) for convenience, and finally, a score of 78.6 (50.0-92.9) and 85.7 (71.4-92.9) for global satisfaction. The median (IQR) reduction in MHD and MMD was 10.0 (3.0-17.0; p < 0.001) and 8.0 (4.0-12.0; p < 0.001) days after 3 months of treatment, and 10.0 (3.0-17.0; p < 0.001) and 9.0 (5.0-17.0; p < 0.001) days after 6 months. The median (IQR) HIT-6 score decreased from 68.0 (65.0-72.0) to 60.0 (51.0-66.0; p < 0.001) at Month 3 and to 56.0 (48.0-64.0; p < 0.001) at Month 6. Finally, the median (IQR) MIDAS score decreased from 70 (40.0-120.0) to 24 (7.8-60.0; p < 0.001) and 17 (5.0-45.0; p < 0.001) at Months 3 and 6, respectively. The median change from baseline in MMD was significantly associated with effectiveness at 3 (β = -0.93, 95% CI -1.34 to -0.53; p < 0.001) and 6 months (β = -1.56, 95% CI -2.15 to -0.97; p < 0.001). Similarly, reductions in MMD were significantly associated with the global satisfaction dimension of the questionnaire (β = -0.82, 95% CI -1.27 to -0.37; p < 0.001) and (β = -1.80, 95% CI -2.42 to -1.18; p < 0.001).</p><p><strong>Conclusions: </strong>Most patients were satisfied with CGRP mAbs' effectiveness, tolerability, and convenience in a real-world setting. Interestingly, increasing TS was associated with meaningful reductions in frequency, impact, and disability caused by migraine.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}